nach oben

Journal of Thrombosis and Thrombolysis

Erschienen in:

08.04.2021

The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF

verfasst von: Rasha Soliman, Hend Mamdouh, Laila Rashed, Mona Hussein

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Much concern was directed towards the crucial role of recombinant tissue plasminogen activator (rt-PA) in improving neuroplasticity in patients with acute ischemic stroke. The aim of the work to investigate the effect of treating patients with acute ischemic stroke with rt-PA, on the level of brain derived neurotrophic factor (BDNF) as a marker of neuroplasticity. This study was conducted on 47 patients presenting with acute ischemic stroke (during the first 4.5 h from stroke onset); 26 patients of them eligible for receiving rt-PA (patient group) and 21 patients having contraindications for treatment with rt-PA (control group). Neurological, radiological and laboratory assessment (including BDNF serum level) were done for both groups at stroke onset (before receiving rt-PA) and at day 7. There was a statistically significant increase in BDNF serum level from day 1 to day 7 in rt-PA treated patients in comparison to control group (P-value˂ 0.001). Serum level of BDNF is significantly higher at the onset of stroke in female patients and non-smokers than males or smokers (P-value = 0.011, 0.01 respectively). There was no effect of either age, body mass index, hypertension, diabetes, drug abuse, past or family history of stroke, valvular heart diseases, atrial fibrillation, cardiomyopathy, ejection fraction, carotid atherosclerotic changes, lipid profile or uric acid, on BDNF serum level measured at the onset of stroke. Treatment of patients with acute ischemic stroke with rt-PA causes significant improvement in neuroplasticity through increasing BDNF serum level.

Feigin VL, Norrving B, Mensah GA (2017) Global burden of stroke. Circ Res 120(3):439–448CrossRef

Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM et al (1997) American heart association prevention conference prevention and rehabilitation of stroke risk factors. Stroke 28(7):1507–1517CrossRef

Zivin JA (2009) Acute stroke therapy with tissue plasminogen activator (tPA) since it was approved by the U.S. food and drug administration (FDA). Ann Neurol 66(1):6–10CrossRef

Saver JL, Filip B, Hamilton S, Yanes A, Craig S, Cho M et al (2010) Improving the reliability of stroke disability grading in clinical trials and clinical practice: the Rankin focused assessment (RFA). Stroke 41(5):992–995CrossRef

Adibhatla RM, Hatcher JF (2008) Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies. CNS Neurol Disord Drug Targets 7(3):243–253CrossRef

Liu Z, Li Y, Zhang L, Xin H, Cui Y, Hanson LR et al (2012) Subacute intranasal administration of tissue plasminogen activator increases functional recovery and axonal remodeling after stroke in rats. Neurobiol Dis 45(2):804–809CrossRef

Ho VM, Lee JA, Martin KC (2011) The cell biology of synaptic plasticity. Science 334(6056):623–628CrossRef

Huang EJ, Reichardt LF (2001) Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24:677–736CrossRef

Pikula A, Beiser AS, Chen TC, Preis SR, Vorgias D, DeCarli C et al (2013) Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury: framingham study. Stroke 44(10):2768–2775CrossRef

10.

Lasek-Bal A, Jedrzejowska-Szypulka H, Rozycka J, Bal W, Holecki M, Dulawa J et al (2015) Low concentration of BDNF in the acute phase of ischemic stroke as a factor in poor prognosis in terms of functional status of patients. Med Sci Monit 21:3900–3905CrossRef

11.

Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S et al (2004) Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306(5695):487–491CrossRef

12.

Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Phil Trans R Soc B Biol Sci 361(1473):1545–1564CrossRef

13.

National Institute of Neurological D., Stroke. NIH stroke scale: Dept. of Health and Human Services, USA; 2011.

14.

Xin H, Li Y, Shen LH, Liu X, Wang X, Zhang J et al (2010) Increasing tPA activity in astrocytes induced by multipotent mesenchymal stromal cells facilitate neurite outgrowth after stroke in the mouse. PLoS ONE 5(2):e9027CrossRef

15.

Rodier M, Quirié A, Prigent-Tessier A, Béjot Y, Jacquin A, Mossiat C et al (2015) Relevance of post-stroke circulating BDNF levels as a prognostic biomarker of stroke outcome. Impact of rt-PA treatment. PLoS ONE 10(10):e0140668CrossRef

16.

Meng Y, Chopp M, Zhang Y, Liu Z, An A, Mahmood A et al (2014) Subacute intranasal administration of tissue plasminogen activator promotes neuroplasticity and improves functional recovery following traumatic brain injury in rats. PLoS ONE 9(9):e106238CrossRef

17.

Rodier M, Prigent-Tessier A, Béjot Y, Jacquin A, Mossiat C, Marie C et al (2014) Exogenous t-PA administration increases hippocampal mature BDNF levels plasmin- or NMDA-dependent mechanism? PLoS ONE 9(3):e92416CrossRef

18.

Ding Q, Ying Z, Gomez-Pinilla F (2011) Exercise influences hippocampal plasticity by modulating brain-derived neurotrophic factor processing. Neuroscience 192:773–780CrossRef

19.

Shen LH, Xin H, Li Y, Zhang RL, Cui Y, Zhang L et al (2011) Endogenous tissue plasminogen activator mediates bone marrow stromal cell-induced neurite remodeling after stroke in mice. Stroke 42(2):459–464CrossRef

20.

Benarroch EE (2007) Tissue plasminogen activator: beyond thrombolysis. Neurology 69(8):799–802CrossRef

21.

Haile WB, Wu J, Echeverry R, Wu F, An J, Yepes M (2012) Tissue-type plasminogen activator has a neuroprotective effect in the ischemic brain mediated by neuronal TNF-alpha. J Cereb Blood Flow Metab 32(1):57–69CrossRef

22.

Echeverry R, Wu J, Haile WB, Guzman J, Yepes M (2010) Tissue-type plasminogen activator is a neuroprotectant in the mouse hippocampus. J Clin Invest 120(6):2194–2205CrossRef

23.

Kim YH, Park JH, Hong SH, Koh JY (1999) Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 284(5414):647–650CrossRef

24.

Cops EJ, Sashindranath M, Daglas M, Short KM, da Fonseca PC, Pang TY et al (2013) Tissue-type plasminogen activator is an extracellular mediator of Purkinje cell damage and altered gait. Exp Neurol 249:8–19CrossRef

25.

Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL et al (2000) Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96(2):569–576CrossRef

26.

Yepes M (2015) Tissue-type plasminogen activator is a neuroprotectant in the central nervous system. Front Cell Neurosci 9:304CrossRef

27.

Weinstein G, Preis SR, Beiser AS, Kaess B, Chen TC, Satizabal C et al (2017) Clinical and environmental correlates of serum BDNF: a descriptive study with plausible implications for AD research. Curr Alzheimer Res 14(7):722–730CrossRef

28.

Chan CB, Ye K (2017) Sex differences in brain-derived neurotrophic factor signaling and functions. J Neurosci Res 95(1–2):328–335CrossRef

29.

Begliuomini S, Casarosa E, Pluchino N, Lenzi E, Centofanti M, Freschi L et al (2007) Influence of endogenous and exogenous sex hormones on plasma brain-derived neurotrophic factor. Hum Reprod 22(4):995–1002CrossRef

30.

Segal M, Murphy D (2001) Estradiol induces formation of dendritic spines in hippocampal neurons: functional correlates. Horm Behav 40(2):156–159CrossRef

31.

Kim TS, Kim DJ, Lee H, Kim YK (2007) Increased plasma brain-derived neurotrophic factor levels in chronic smokers following unaided smoking cessation. Neurosci Lett 423(1):53–57CrossRef

32.

Yeom M, Shim I, Lee HJ, Hahm DH (2005) Proteomic analysis of nicotine-associated protein expression in the striatum of repeated nicotine-treated rats. Biochem Biophys Res Commun 326(2):321–328CrossRef

33.

Bhang SY, Choi SW, Ahn JH (2010) Changes in plasma brain-derived neurotrophic factor levels in smokers after smoking cessation. Neurosci Lett 468(1):7–11CrossRef

34.

Xiaoyu W (2015) The exposure to nicotine affects expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in neonate rats. Neurol Sci 36(2):289–295CrossRef

35.

Gajewska E, Sobieska M, Lojko D, Wieczorowska-Tobis K, Suwalska A (2014) Obesity itself does not influence BDNF serum levels in adults. Eur Rev Med Pharmacol Sci 18(21):3246–3250PubMed

36.

Marchelek-Mysliwiec M, Cichocka E, Dziedziejko V, Dutkiewicz GZ, Stepniewska J, Safranow K et al (2015) Insulin resistance and brain-derived neurotrophic factor levels in chronic kidney disease. Ann Clin Biochem 52(Pt 2):213–219CrossRef

37.

Jin H, Chen Y, Wang B, Zhu Y, Chen L, Han X et al (2018) Association between brain-derived neurotrophic factor and von Willebrand factor levels in patients with stable coronary artery disease. BMC Cardiovasc Disord 18(1):23CrossRef

38.

Prigent-Tessier A, Quirié A, Maguin-Gaté K, Szostak J, Mossiat C, Nappey M et al (2013) Physical training and hypertension have opposite effects on endothelial brain-derived neurotrophic factor expression. Cardiovasc Res 100(3):374–382CrossRef

39.

Jiang H, Liu Y, Zhang Y, Chen ZY (2011) Association of plasma brain-derived neurotrophic factor and cardiovascular risk factors and prognosis in angina pectoris. Biochem Biophys Res Commun 415(1):99–103CrossRef

40.

Qiu Shichao RJ, Luo Hui, Hu Xuejian, Hou Yuanhua (2014) Correlation between BDNF, VEGF and carotid atherosclerosis in type 2 diabetes mellitus. J Second Mil Med Univ 35(8):920–923.

41.

Zhang J, Zhang X, Su H, Tao J, Xie Y, Han B et al (2014) Increased serum brain-derived neurotrophic factor levels during opiate withdrawal. Neurosci Lett 571:61–65CrossRef

42.

Angelucci F, Ricci V, Pomponi M, Conte G, Mathé AA, Attilio Tonali P et al (2007) Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. J Psychopharmacol 21(8):820–825CrossRef

Titel: The use of recombinant tissue plasminogen activator in in acute ischemic stroke is associated with increased level of BDNF
verfasst von: Rasha Soliman
Hend Mamdouh
Laila Rashed
Mona Hussein
Publikationsdatum: 08.04.2021
Verlag: Springer US
Erschienen in: Journal of Thrombosis and Thrombolysis / Ausgabe 4/2021
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-021-02443-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

VHF-Ablation nützt wohl nur bei reduzierter Auswurfleistung

02.05.2024 Ablationstherapie Nachrichten

Ob die Katheterablation von Vorhofflimmern bei Patienten mit Herzinsuffizienz die Komplikationsraten senkt, scheint davon abzuhängen, ob die Auswurfleistung erhalten ist oder nicht. Das legen die Ergebnisse einer Metaanalyse nahe.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2021

Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody

Prior use of anticoagulation is associated with a better survival in COVID-19

Screening for venous thromboembolism in patients with COVID-19

A rare case of non-traumatic spinal epidural hematoma in lumbar region associated with apixaban therapy

External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19